We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Custom CAR-T Development Service

Custom CAR-T Development Service content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

AMSBIO has announced a custom Chimeric Antigen Receptor T cell (CAR-T) service designed to take advantage of the clinical breakthroughs achieved with CAR-T cells in various hematological malignancies.

CAR-T cell therapy is a type of immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatible complex molecules. The CAR-T cell therapies have been widely used in the treatment of hematological malignancies, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphoma, and multiple myeloma.

Drawing upon its expertise in monoclonal antibody development (rabbit and mouse), AMSBIO’s custom development service aims to provide assistance in design, planning and executing CAR-T studies, whether in the preclinical, clinical or proof of concept stage. The AMSBIO CAR-T platform can also start with a target molecule (Phase I) or antibody (Phase II).

As part of their custom CAR-T development service – AMSBIO construct the single chain variable fragment (ScFv), transfer it into the CAR lentivector of choice, make lentivirus and transduce activated human (or mouse) T cells. After the CAR-T cells proliferate, the cytotoxicity is measured in a real time assay, CAR expression analyzed and cytokine production quantified.